DUBLIN and MYSTIC, Conn., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Wednesday, November 10, 2010 at 11:00 am Eastern Time (4:00 pm UTC/GMT) to discuss selected financial and operating results from the third quarter, including a progress update of the Company's MARINE and ANCHOR trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels in separate patient populations.
The conference call may be heard live via the investor relations section of the Company's website at www.amarincorp.com and will also be available by dialing the following numbers:From outside U.S. dial-in:
(201) 689-8565 From inside U.S. dial-in:
(877) 407-0778Replay will be made available for a period of two weeks following the conference calls. To hear a replay of the call dial 1-201-612-7415 (outside U.S.) 1-877-660-6853 (inside U.S.). For both dial in numbers please use account number is 286 and conference id 359371.
About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.
Contacts:Investor Contact Information: John F. TheroChief Financial OfficerIn US: +1 (860) 572 4979 email@example.comLee M. SternThe Trout GroupIn U.S. +1 (646) firstname.lastname@example.orgInternational Media Contact Information: Mark Swallow or David DibleCitigate Dewe RogersonIn UK: +44 (0)207 638 email@example.com
|SOURCE Amarin Corporation plc|
Copyright©2010 PR Newswire.
All rights reserved